SEC filings
Bio-Techne (TECH)
Recent filings Bio-Techne made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000842023All filings on SEC.gov
10-QQuarterly report
Quarterly report
Bio-Techne's net sales rose 5% to $299.7 million in the quarter ended September 30, 2026, with organic revenue up 7%. Shareholders approved the company's pending acquisition by Merck KGaA, which is expected to close in late 2026 or early…
8-KCurrent report
Other Events
Bio-Techne's board of directors declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026, payable November 23, 2026 to shareholders of record as of November 13, 2026, provided the company's pending…
8-KCurrent report
Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
Bio-Techne shareholders approved the company's merger agreement with Merck KGaA, Darmstadt, Germany, at a special meeting, while a non-binding advisory proposal on merger-related executive compensation failed. …
8-KCurrent report
Other Events
Bio-Techne disclosed supplemental proxy disclosures for its pending merger with Merck KGaA after a purported shareholder lawsuit seeking to enjoin the shareholder vote and demand letters alleged the proxy statement misrepresented or…
10-KAnnual report
Annual report
Bio-Techne reported flat fiscal 2026 net sales of $1.2 billion and a 148% rise in consolidated net earnings, while its pending merger with Merck KGaA would give shareholders $73.00 per share in cash. …
8-KCurrent report
Results of Operations and Financial Condition; Other Events
Bio-Techne reported fourth-quarter fiscal 2026 organic revenue growth of 3% and flat full-year revenue, and announced a cash dividend. As previously announced, Bio-Techne agreed to be acquired by Merck KGaA for $73 per share in cash, an…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Bio-Techne in Readster
Add Bio-Techne to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.